BindingDB logo
myBDB logout

204 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28557458 16 Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.EBI Novartis Institutes for BioMedical Research
27789138 355 Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.EBI AbbVie Bioresearch Center
28004573 82 Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.EBI The Institute of Cancer Research
28088086 5 Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives.EBI University of Sharjah
28280261 84 Non-kinase targets of protein kinase inhibitors.EBI The University of Sydney
27816515 143 Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.EBI Merck & Co.
27777009 11 Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit.EBI Jiangxi Science & Technology Normal University
27288186 29 Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents.EBI Peking University Health Science Center
27246618 73 GSK114: A selective inhibitor for elucidating the biological role of TNNI3K.EBI GlaxoSmithKline
27010810 24 Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.EBI OriBase Pharma
26852623 2 Natural Products as Sources of New Drugs from 1981 to 2014.EBI NIH Special Volunteer
27089211 38 Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.EBI Zhejiang University
27155899 30 Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.EBI Jilin University
27085672 151 Purinylpyridinylamino-based DFG-in/aC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.EBI Amgen Inc
26724730 12 Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.EBI Semmelweis University
26810260 3 Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation.EBI Hanyang University
26804230 48 Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG.EBI Takeda Pharmaceutical Co., Ltd
26739779 15 Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers.EBI Shanghai Hengrui Pharmaceutical Co., Ltd
26762835 342 Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).EBI Icahn School of Medicine at Mount Sinai
26396681 58 Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.EBI Novartis Institutes for BioMedical Research
26318998 1 Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway.EBI Trinity College
26318067 34 Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors.EBI Hanyang University
26355916 106 Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).EBI GlaxoSmithKline
25662701 23 Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3▀ inhibitors and neuroprotective agents.EBI Zhejiang University
25007344 73 Optimization of potent DFG-in inhibitors of platelet derived growth factor receptor▀ (PDGF-R▀) guided by water thermodynamics.EBI Christian-Albrechts-University of Kiel
25965804 80 Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.EBI Eli Lilly and Company
26005534 158 (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.EBI Genomics Institute of the Novartis Research Foundation
26005530 20 N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.EBI Guangzhou Institutes of Biomedicine and Health
25835317 63 Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.EBI Sichuan University
25611072 20 Structural investigation of B-Raf paradox breaker and inducer inhibitors.EBI UMR CNRS-Universit£ d'Orl£ans 7311
25587754 146 Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).EBI Amgen Inc
25461318 8 Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.EBI China Pharmaceutical University
25086238 13 Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.EBI Shenyang Pharmaceutical University
24878193 8 Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.EBI Hanyang University
25462267 39 Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.EBI China Pharmaceutical University
25440879 13 Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.EBI Shenyang Pharmaceutical University
25313996 91 Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.EBI Merck Research Laboratories
25267006 1 Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.EBI Nanjing University
25221654 39 Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors.EBI Novartis Institutes for BioMedical Research
24858546 46 Guanidinium-based derivatives: searching for new kinase inhibitors.EBI Trinity College
24773549 20 Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic properties.EBI Development Center for Biotechnology
24675135 4 Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.EBI Peking Union Medical College & Chinese Academy of Medical Sciences
24424304 10 Recent progress in the identification of BRAF inhibitors as anti-cancer agents.EBI Cairo University
23906342 14 Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives.EBI Takeda Pharmaceutical Co., Ltd
24389511 25 Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.EBI Zhejiang University
23755884 23 Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.EBI Takeda Pharmaceutical Co., Ltd
23623674 1 Synthetic approaches to the 2011 new drugs.EBI Shenogen Pharma Group
23498918 41 Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor.EBI Takeda Pharmaceutical Co., Ltd
23490150 48 Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors.EBI Takeda Pharmaceutical Co., Ltd
23398453 4 Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.EBI AstraZeneca
23218715 36 The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.EBI GlaxoSmithKline
22537109 25 Identification of a novel family of BRAF(V600E) inhibitors.EBI University of Pennsylvania
19303774 87 1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3.EBI GlaxoSmithKline
23147077 23 Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.EBI Takeda Pharmaceutical Co., Ltd
23123015 22 Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors.EBI Takeda Pharmaceutical Co., Ltd
22883026 34 Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.EBI Takeda Pharmaceutical Co., Ltd
22726925 216 Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.EBI Cellzome Ltd
22808911 18 Conformation-specific effects of Raf kinase inhibitors.EBI Takeda California Inc
22980219 55 Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.EBI Takeda Pharmaceutical Co., Ltd
22704238 18 Design, synthesis and biological evaluation ofß-carboline derivatives as novel inhibitors targeting B-Raf kinase.EBI China Pharmaceutical University
22439974 79 Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.EBI Takeda Pharmaceutical Co., Ltd
22335519 3 Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.EBI Genentech
22583669 1 Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.EBI Nanjing University
22168626 32 Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.EBI Ambit Biosciences
22185282 32 Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases.EBI Islamic University of Gaza
15975507 13 Features of selective kinase inhibitors.EBI University of California San Francisco
18183025 12060 A quantitative analysis of kinase inhibitor selectivity.EBI Ambit Biosciences
17850214 99 The selectivity of protein kinase inhibitors: a further update.EBI University of Dundee
18662874 20 Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.EBI GlaxoSmithKline
18077425 197 Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.EBI Harvard Medical School
18434146 28 Dual binding site inhibitors of B-RAF kinase.EBI Johnson & Johnson Pharmaceutical Research & Development
18278858 93 Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.EBI Amgen Inc
16260133 43 The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.EBI GlaxoSmithKline
22377675 44 Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.EBI Westf£lische Wilhelms-Universit£t M£nster
16249345 25 Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.EBI GlaxoSmithKline
22222036 9 Small molecule inhibitors of BRAF in clinical trials.EBI The Institute of Cancer Research
22196123 23 Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.EBI Sejong University
22137342 26 Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.EBI Celgene Corporation
22024030 22 Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors.EBI Pfizer Inc
22003817 71 Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.EBI Takeda Pharmaceutical Co., Ltd
22037378 31824 Comprehensive analysis of kinase inhibitor selectivity.EBI Ambit Biosciences
21873050 6 Identification of novel BRAF kinase inhibitors with structure-based virtual screening.EBI Sejong University
21561767 48 Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.EBI ARIAD Pharmaceuticals Inc
21536432 54 Non-oxime pyrazole based inhibitors of B-Raf kinase.EBI Array BioPharma
20634068 2 Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.EBI Millennium Pharmaceuticals Inc
21341678 49 Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.EBI Millennium Pharmaceuticals Inc
24900231 22 Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.EBI TBA
20965724 57 Identification of potent ITK inhibitors through focused compound library design including structural information.EBI Nycomed GmbH
20961062 42 Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.EBI Pfizer Inc
20800479 33 Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.EBI Deciphera Pharmaceuticals LLC
20833055 44 Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.EBI Takeda Pharmaceutical Co., Ltd
19654408 2521 AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).EBI Ambit Biosciences
16783341 34 Rational design of inhibitors that bind to inactive kinase conformations.EBI Novartis Research Foundation
20621496 31 The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.EBI The University of Arizona
20307980 22 B-Raf kinase inhibitors: hit enrichment through scaffold hopping.EBI Wyeth Research
19884006 47 Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors.EBI Wyeth Research
19969400 4 5-Substituted [1]pyrindine derivatives with antiproliferative activity.EBI University of Paris
19864136 45 Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.EBI Wyeth Research
19854649 49 Discovery of highly potent and selective type I B-Raf kinase inhibitors.EBI Wyeth Research
20148563 42 BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.EBI The Institute of Cancer Research
19875283 41 Novel pyrazolopyrimidines as highly potent B-Raf inhibitors.EBI Wyeth Research
19362830 47 Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.EBI Wyeth Research
19356929 17 Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.EBI Boehringer Ingelheim Pharmaceuticals Inc
19317452 155 Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.EBI Wyeth Research
18815050 34 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.EBI Wyeth Research
17574417 98 SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.EBI Bayer Research Center
16392826 68 Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.EBI Institute of Cancer Research
15317461 53 Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.EBI GlaxoSmithKline
32340792 16 Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting EBI National Research Centre (NRC ID: 60014618)
32305182 48 Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.EBI Shenyang Pharmaceutical University
31757666 314 Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.EBI Merck & Co.
27491711 422 Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.EBI Merck and Co.
30660499 42 Discovery of highly potent V600E-B-RAF kinase inhibitors: Molecular modeling study.EBI University of Sharjah
31789518 11 Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.EBI Purdue University
31284081 60 Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.EBI National Research Centre
31053508 34 Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.EBI China Pharmaceutical University
30977659 35 Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.EBI University of South Carolina
31693351 473 Discovery of 4EBI TBA
31312411 15 Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases.EBI University of Southern California
31252305 18 Light-controlled inhibition of BRAFV600E kinase.EBI University Medical Center Groningen
32223235 12 Discovery of Selective Small Molecule Degraders of BRAF-V600E.EBI Cullgen Inc.
31244114 56 Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-? Motif Kinase (ZAK) Inhibitors.EBI Jinan University
31059256 28 Design and Discovery of EBI Novartis Institutes for BioMedical Research
30630714 33 Design, synthesis, and in vitro evaluation of N-(3-(3-alkyl-1H-pyrazol-5-yl) phenyl)-aryl amide for selective RAF inhibition.EBI Hanyang University
30600149 35 The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.EBI University of South China
30529543 57 Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance.EBI China Pharmaceutical University
30613326 32 Privileged Structures and Polypharmacology within and between Protein Families.EBI The Institute of Cancer Research
30384048 365 ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.EBI University of Florida
31520926 28 Discovery of a potent p38?/MAPK14 kinase inhibitor: Synthesis, inávitro/inávivo biological evaluation, and docking studies.EBI University of Sharjah
30006168 1 Synthesis, inávitro antiproliferative activity, and kinase inhibitory effects of pyrazole-containing diarylureas and diarylamides.EBI University of Sharjah
27017549 15 Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.EBI Korea Institute of Science and Technology (KIST)
24675381 47 Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.EBI Array BioPharma, Inc.
31200237 95 Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.EBI Shanghai Pharmaceuticals Holding Co., Ltd.
24042006 78 Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.EBI Array BioPharma Inc.
23489628 6 Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors.EBI Central South University
23376011 37 Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.EBI The Institute of Cancer Research
30978288 113 A Selective and Brain Penetrant p38?MAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.EBI Northwestern University
23116892 1 Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.EBI Pfizer Inc.
22954737 28 Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.EBI Array BioPharma
22858139 25 Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors.EBI Chinese Academy of Sciences
22763369 1 Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption.EBI Takeda Pharmaceutical Company Limited
22196124 48 Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.EBI Array BioPharma, Inc.
22534450 36 The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.EBI Array BioPharma, Inc.
22361686 3 Design, synthesis and biological evaluation of novel (E)-?-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.EBI Nanjing University
22264479 56 Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.EBI Novartis Institutes for Biomedical Research
24900315 42 Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.EBI Array BioPharma
22209462 16 Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.EBI Array BioPharma
21807507 55 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.EBI Ambit Biosciences Corporation
21802293 69 Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.EBI ArrayBioPharma
20667740 32 Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.EBI The Institute of Cancer Research
20597484 170 Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.EBI The Institute of Cancer Research
20199087 91 Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.EBI The Institute of Cancer Research
20149658 1 Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.EBI Korea Institute of Science and Technology
19271717 96 Bioactive metabolites from the endophytic fungus Stemphylium globuliferum isolated from Mentha pulegium.EBI Heinrich-Heine-Universitat
19473026 80 Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.EBI The Institute of Cancer Research
18494522 244 Cytotoxic metabolites from the fungal endophyte Alternaria sp. and their subsequent detection in its host plant Polygonum senegalense.EBI Heinrich-Heine-Universit£t
30216849 18 Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.EBI University of Science & Technology (UST)
29940463 46 Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAFEBI Nanjing University
29578342 35 Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.EBI Yunnan University
30085668 41 Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.EBI Institute of Cancer Research
29727562 14 N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.EBI University of Pennsylvania
29549841 8 Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.EBI Beni-Suef University
29407977 30 Effects of rigidity on the selectivity of protein kinase inhibitors.EBI University of Southern California
29631788 68 Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-RafEBI Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University)
29266937 36 Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?EBI University of South Australia
29461827 35 Current Insights of BRAF Inhibitors in Cancer.EBI Albert Einstein College of Medicine
28505447 30 Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.EBI Temple University
29107542 35 Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors.EBI Novartis Institutes for Biomedical Research
28927801 16 Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.EBI Jiangxi Science & Technology Normal University
29886324 28 Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFEBI Southern Medical University
29107425 90 Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.EBI Korea Institute of Science and Technology (KIST)
29032031 91 Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.EBI Xi'an Jiaotong University
29102175 91 Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.EBI Xi'an Jiaotong University
28586211 40 Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-? Motif Kinase (ZAK) Inhibitors.EBI University of Macau
28242553 36 Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.EBI China Pharmaceutical University
29561151 58 4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) Inhibitors.EBI TBA
21985426 27 Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.BDB Ondokuz Mayis University
15831442 46 Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.BDB Taisho Pharmaceutical Co., Ltd
15798001 56 Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2.BDB Kyowa Hakko Kogyo Co., Ltd
2904784 109 Neuroleptic binding to human brain receptors: relation to clinical effects.BDB Mayo Clinic
2017157 12 Regulation of dopamine D2 receptors by sodium and pH.BDB Medical Research Service
19549076 26 Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.BDB Universita degli Studi di Firenze
1828505 19 Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain.BDB University of Pennsylvania
19811924 23 Development of a highly water-soluble peptide-based human neutrophil elastase inhibitor; AE-3763 for treatment of acute organ injury.BDB Dainippon Sumitomo Pharma Co
17949010 16 Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.BDB Pfizer Inc
15115388 36 Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity.BDB Merck Research Laboratories
17915852 6 Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs.BDB University of Pavia